Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nazartinib versus erlotinib or gefitinib as first-line treatment for EGFR-mutant advanced non-small cell lung cancer
2017-003998-34Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nazartinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started May 2018; status: terminated.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-003998-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003998-34.